Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction
2014 (English)In: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 371, no 11, 1016-1027 p.Article in journal (Refereed) Published
BACKGROUND The direct-acting platelet P2Y(12) receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown. METHODS We conducted an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI of less than 6 hours duration, comparing prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) treatment with ticagrelor. The coprimary end points were the proportion of patients who did not have a 70% or greater resolution of ST-segment elevation before percutaneous coronary intervention (PCI) and the proportion of patients who did not have Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-related artery at initial angiography. Secondary end points included the rates of major adverse cardiovascular events and definite stent thrombosis at 30 days. RESULTS The median time from randomization to angiography was 48 minutes, and the median time difference between the two treatment strategies was 31 minutes. The two coprimary end points did not differ significantly between the prehospital and in-hospital groups. The absence of ST-segment elevation resolution of 70% or greater after PCI (a secondary end point) was reported for 42.5% and 47.5% of the patients, respectively. The rates of major adverse cardiovascular events did not differ significantly between the two study groups. The rates of definite stent thrombosis were lower in the prehospital group than in the in-hospital group (0% vs. 0.8% in the first 24 hours; 0.2% vs. 1.2% at 30 days). Rates of major bleeding events were low and virtually identical in the two groups, regardless of the bleeding definition used. CONCLUSIONS Prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion.
Place, publisher, year, edition, pages
Massachusetts Medical Society , 2014. Vol. 371, no 11, 1016-1027 p.
Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:liu:diva-111259DOI: 10.1056/NEJMoa1407024ISI: 000341382800007PubMedID: 25175921OAI: oai:DiVA.org:liu-111259DiVA: diva2:755600
Funding Agencies|AstraZeneca; Bayer; Boehringer Ingelheim; Cardiovascular Research Foundation; Europa Organisation; Gerson Lehrman Group; Iroko Cardio International; Lead-Up; Luminex; McKinsey and Company; Remedica; Servier; TIMI Study Group; WebMD; Wolters Kluwer Health; Bristol-Myers Squibb; Biotronik; Eli Lilly; Medicines Company; Menarini Group; Roche; Sanofi-Aventis; Pfizer; Daiichi-Sankyo; Medtronic; Menarini; Accumetrics; Abbott Laboratories; Nanosphere; Stentys; Correvio; Merck Serono; Regeneron; Novartis; PlaqueTec; Merck Sharp; Dohme; bioM rieux; European Cardiovascular Research Center; Celgene; Fresenius; Fresenius, LFB2014-10-152014-10-142015-03-31